Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07690527
PHASE1

Long-Term Follow-up Study for RB001 Gene Therapy Study in Children With SHANK3-related Phelan McDermid Syndrome (PMS)

Sponsor: Peking University First Hospital

View on ClinicalTrials.gov

Summary

This is a long-term follow-up study of participants in the RB001-101 gene replacement therapy clinical trial for Children With SHANK3-related Phelan-McDermid Syndrome (PMS). Participants will roll over from the parent study into this long-term study for continuous safety monitoring and preliminary efficacy assessment for up to 5 years.

Official title: A Long-term Follow-up Study of an Open-label, Single-arm, Single-dose Escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intracerebroventricular Injection of RB001 in Participants With SHANK3-related Phelan-McDermid Syndrome.

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

8

Start Date

2026-08-01

Completion Date

2031-12-01

Last Updated

2026-07-08

Healthy Volunteers

No

Interventions

BIOLOGICAL

RB001

The study enrolled up to 2 cohorts, evaluating a higher or lower dose

Locations (1)

Peking University First Hospital

Beijing, China, China